Supply Chain Considerations for COVID-19 Vaccine Manufacturing [November 23, 2020]   [open pdf - 573KB]

From the Document: "The development of a vaccine for the Coronavirus Disease 2019 (COVID-19) pandemic has been of concern to Congress, as vaccination can be one of the most effective methods of preventing disease spread. On November 18, 2020, Pfizer/BioNTech announced that an interim analysis found its newly developed vaccine to be '95% effective against COVID-19' and has since filed for an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration. On November 16, 2020, Moderna announced that its vaccine, tentatively evaluated as 94.5% effective, will also be submitted for an EUA. According to media reports, 'Moderna said it would have 20 million doses ready by the end of 2020; Pfizer said it would have about 50 million by then.' Providing COVID-19 vaccines--complex, specially manufactured and distributed products--involves significant supply chain considerations. Needed supplies may be limited in quantity and face global competition. This Insight provides an overview of selected supplies required to manufacture vaccines and ancillary vaccination materials that may pose supply chain challenges and describes the federal government's role in this process. It does not cover particular contracts issued, or supplies potentially required for transportation, distribution, and administration of eventual vaccines."

Report Number:
CRS Insight, IN11544
Public Domain
Retrieved From:
Congressional Research Service: https://crsreports.congress.gov/
Media Type:
Help with citations